Sun Pharmaceuticals Industries Ltd - SUN PHARMA.INDS. Share Price

Sector: Pharmaceuticals | ISIN: INE044A01036
₹ 1,139.95 (1.25%) icon27 Sep, 2023, 3:57:39 PM
Open
₹ 1,126.15
Prev. Close
₹ 1,125.85
Turnover(lac)
₹ 26,583.84
Day's High
₹ 1,145.90
Day's Low
₹ 1,123.20
52 Wk High
₹ 1,169.70
52 Wk Low
₹ 892.05
Book Value
₹ 100.57
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 273,512.19
P/E
66.02
EPS
17.27
Div. Yield
1.01

Sun Pharmaceuticals Industries Ltd Stock View

info icon
Edit Image
BUY
Target | 19 Sep, 2023 1,226.36 (7.58%)

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide ran... Read More

Sun Pharmaceuticals Industries Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/27/2023 3:57:39 PM

    ₹ 1139.95 14.10 1.25
  • Open
  • ₹ 1,126.15
  • Prev. Close
  • ₹ 1,125.85
  • Turnover(Lac.)
  • ₹ 26,584
  • Day's High
  • ₹ 1,145.9
  • Day's Low
  • ₹ 1,123.2
  • 52 Week's High
  • ₹ 1,169.7
  • 52 Week's Low
  • ₹ 892.05
  • Book Value
  • ₹ 100.57
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 273,512.19
  • P/E
  • 66.02
  • EPS
  • 17.27
  • Divi. Yield
  • 1.01

Sun Pharmaceuticals Industries Ltd Corporate Actions

07 Jul , 2023

12:00 AM

AGM

Announcement date: 07 Jul , 2023

View Details

11 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 Jul , 2023

12:00 AM

26 May , 2023

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 26 May , 2023

View Details

11 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jan , 2023

12:00 AM

Dividend

Dividend amount: 7.5
Announcement date: 31 Jan , 2023

View Details

16 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

16 Jan , 2023

12:00 AM

10 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Oct , 2022

12:00 AM


Sun Pharmaceuticals Industries Ltd News and Update

Image not found
  • 12 hours ago |
  • 8:33 PM

Sun Pharma, IndusInd Bank, Larsen & Toubro and UltraTech Cement were among the gainers on Sensex.

Image not found
Image not found
  • IIFL News Service |
  • 1 day ago |
  • 8:31 PM
Image not found
  • IIFL News Service |
  • 25 September, 2023 |
  • 8:30 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Sun Pharmaceuticals Industries Ltd SHAREHOLDING SNAPSHOT
28 September , 2023 | 04:15 AM

PROMOTER - TOTAL54.48%

Indian: 54.48%

Foreign: 0%

NON-PROMOTER - TOTAL 45.52%

Institutions: 36.23%

Non-Institutions: 9.29%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Sun Pharmaceuticals Industries Ltd FINANCIALS

Sun Pharmaceuticals Industries Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Sun Pharmaceuticals Industries Ltd

  • Dilip S Shanghvi
  • Managing Director
  • Sudhir V Valia
  • Non-Exec & Non-Independent Dir
  • Sailesh T Desai
  • Whole-time Director
  • Gautam Doshi
  • Non-Exec. & Independent Dir.
  • Pawan Goenka
  • Lead Independent Director
  • Rama Bijapurkar
  • Independent Director
  • Anoop Deshpande
  • Company Sec. & Compli. Officer
  • Sanjay K Asher
  • Independent Director
  • Rolf Hoffmann
  • Independent Director
  • Aalok Shanghvi
  • Whole Time Director

Summary

Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.The company has global presence with 43 manufacturing facilities across the world. India and the US are two predominant markets, accounting for nearly 70% of the companys revenue. The company has a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil... Read More


Reports by Sun Pharmaceuticals Industries Ltd


Reports by Sun Pharmaceuticals Industries Ltd

Company FAQ

No Record Found